Ipamorelin Half Life

What is the half life of ipamorelin?

Published figures place ipamorelin's half-life at roughly 2 hours, but high-quality human pharmacokinetic data is limited, so the number should be read as approximate.

Ipamorelin is a small synthetic pentapeptide that acts as a ghrelin-receptor agonist and a selective GH secretagogue (Raun et al., 1998). The original characterization work by Raun et al., 1998 focused on its selectivity: it prompts GH release while sparing the increases in cortisol and prolactin seen with some earlier secretagogues. That paper established the pharmacology of the compound in preclinical models. What it does not give the field is a large, replicated human PK dataset with a tightly confirmed elimination half-life.

Because of that gap, the "about 2 hours" figure that circulates widely should be treated as an estimate rather than a settled clinical constant. Where a claim needs a precise human half-life value with a named trial, the honest answer is that the public peer-reviewed record is thin. Researchers generally describe ipamorelin as short-acting, consistent with the brief GH pulse it produces.

Why does ipamorelin have a short duration of action?

The short window reflects its class: selective GH secretagogues are built to mimic a natural, pulsatile GH signal rather than to hold receptors occupied for long periods.

Ipamorelin binds the ghrelin (GH secretagogue) receptor and drives a discrete rise in GH, then clears (Raun et al., 1998). This is different by design from analogs engineered for sustained exposure. For example, CJC-1295 was modified to extend its presence and produced sustained GH and IGF-1 elevations in human study (Teichman et al., 2006). Ipamorelin sits at the opposite end: a brief, selective push.

The practical research consequence is that ipamorelin's effect is tied to its pulse. A short half-life means the compound is present for a limited window, which is why the literature frames it as a pulsatile secretagogue.

How does ipamorelin compare with other GH secretagogues?

Ipamorelin is the selective, short-acting option; other secretagogues differ in duration and in their effect on other hormones.

The table below summarizes what named research reports about each compound. Half-life entries are qualified where public human data is limited.

The contrast that matters for a PK question: ipamorelin is the short, selective member of the group, while CJC-1295 and MK-677 are structured for longer exposure (Teichman et al., 2006; Nass et al., 2008).

What dose ranges has research reported for ipamorelin?

Research on ipamorelin has largely been preclinical, and the public record does not offer a well-replicated human dosing table, so any range should route to a qualified clinician.

The foundational pharmacology comes from Raun et al., 1998, which characterized ipamorelin's action and selectivity in animal models rather than defining a standard human dose. Because a strong human dose-response and PK dataset is not established in the peer-reviewed literature, this page does not state a human dose range as guidance. What can be said plainly: the compound is short-acting and selective (Raun et al., 1998), and personal protocol decisions belong with a licensed clinician, not a web page.

Does a short half-life change how researchers think about ipamorelin?

Yes: a short half-life shapes the compound's role as a pulse-style secretagogue rather than a sustained-exposure agent.

Because the GH rise ipamorelin produces is brief, studies frame it around the pulse it generates rather than around steady-state levels (Raun et al., 1998). This is the opposite of the sustained-exposure logic behind CJC-1295 (Teichman et al., 2006) or the once-daily oral profile of MK-677 (Nass et al., 2008). The takeaway is descriptive, not prescriptive: duration is a defining property of the molecule, and it separates the selective secretagogue class from longer-acting analogs.